Heart failure & cardiomyopathies
Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure
- prematurely terminated
- Prematurely terminated due to challenges in participant management related to the COVID-19 pandemic
Authors' conclusion
PRIORITIZE-HF was terminated prematurely due to COVID-19 and did not demonstrate a statistically significant increase in the intensity of RAAS inhibitor therapies with the potassium-reducing agent SZC compared with placebo.
Study context
- Population
- Patients with symptomatic heart failure and reduced ejection fraction (HFrEF)randomized
- Participants
- 182 patients
- Comparison
- Sodium zirconium cyclosilicate (SZC) vs placebo to intensify renin-angiotensin-aldosterone system (RAAS) inhibitor therapy
- Primary endpoint
- Distribution of patients by RAAS inhibitor category: (i) any RAAS inhibitor < target dose, no MRA; (ii) any RAAS inhibitor at target dose, no MRA; (iii) MRA < target dose; (iv) MRA at target dose
- Follow-up
- 12 weeks
Methodological detailsinternational, multicentre, parallel-group, double-blind, placebo-controlled
- International
- Multicentre
- Parallel-group
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Distribution by RAAS inhibitor treatment category · 3 months
- SZC vs Placebo: P = 0.43
Further findings
Patients at target MRA dose · numerically higher with SZC
Safety
Tolerability
- SZC was well tolerated
Original publication
Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure. ESC Heart Fail. Published 23 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →